Compare GLU & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GLU | ELTX |
|---|---|---|
| Founded | 2004 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 114.7M | 63.3M |
| IPO Year | N/A | 2014 |
| Metric | GLU | ELTX |
|---|---|---|
| Price | $19.09 | $2.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | 6.6K | ★ 261.7K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | ★ 8.60% | N/A |
| EPS Growth | N/A | ★ 39.29 |
| EPS | ★ 0.62 | N/A |
| Revenue | N/A | ★ $2,301,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $31.10 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $17.68 | $2.36 |
| 52 Week High | $21.69 | $16.00 |
| Indicator | GLU | ELTX |
|---|---|---|
| Relative Strength Index (RSI) | 42.19 | 27.22 |
| Support Level | $18.90 | N/A |
| Resistance Level | $19.66 | $3.32 |
| Average True Range (ATR) | 0.22 | 0.14 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 7.18 | 5.88 |
Gabelli Global Utility & Income Trust is a non-diversified, closed-end management investment company. The Fund's objective is to seek a consistent level of after-tax total return. It predominantly invests in stocks of companies involved to a substantial extent in providing products, services, or equipment for the generation or distribution of electricity, gas, or water and infrastructure operations, and in equity securities including preferred securities of companies in other industries, in each case in such securities that are expected to pay periodic dividends.
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.